Can I Take Quercetin with NMN/NR?

Why People Stack Quercetin and NMN/NR

The longevity supplement space has popularized "senolytic + NAD+" stacking, pairing a compound that clears damaged senescent cells with one that raises cellular NAD+ levels. Quercetin, often combined with dasatinib in preclinical senolytic protocols, is the flavonoid half of that equation. NMN and NR supply the raw material cells need to synthesize NAD+, a coenzyme central to mitochondrial energy production, DNA repair, and sirtuin activation.

The NAD+ Decline Problem

NAD+ levels drop roughly 50% between ages 40 and 60 in human tissue samples, according to a 2019 analysis published in Cell Metabolism [1]. That decline is associated with mitochondrial dysfunction, impaired DNA repair, and age-related metabolic disease. NMN and NR are the two most studied oral precursors for restoring NAD+ biosynthesis. A 2022 randomized controlled trial (N=80) published in Science showed that oral NMN at 600 to 900 mg/day increased blood NAD+ metabolites by 38 to 51% over 60 days in middle-aged adults [2].

Quercetin as a Senolytic

Quercetin gained clinical attention after Kirkland and colleagues at Mayo Clinic demonstrated that the dasatinib plus quercetin combination selectively cleared senescent cells in a first-in-human pilot trial (N=14) among patients with diabetic kidney disease, published in EBioMedicine in 2019 [3]. On its own, quercetin is a flavonoid found in onions, apples, and capers. It inhibits the anti-apoptotic PI3K/AKT pathway in senescent cells, and it also modulates histamine release and NF-kB signaling.

Why the Combination Appeals

The logic is straightforward: remove damaged cells (quercetin), then supply the building blocks for healthy cells to repair and generate energy (NMN/NR). No clinical trial has tested this exact pairing. The theoretical framework, though, draws on independent lines of evidence that are each well-supported.

Pharmacokinetic Interaction Analysis

The primary pharmacokinetic concern with quercetin is its activity as an inhibitor of cytochrome P450 enzymes, specifically CYP3A4, CYP2C9, and CYP1A2. An in vitro study published in Drug Metabolism and Disposition found that quercetin inhibits CYP3A4 with an IC50 of approximately 1.1 to 11.7 µM depending on the substrate [4]. This is clinically relevant for drugs like cyclosporine, statins, and certain calcium channel blockers that rely heavily on CYP3A4 for first-pass metabolism.

NMN and NR Bypass CYP Metabolism

NMN is not a xenobiotic processed through hepatic phase I metabolism. After oral ingestion, NMN is absorbed through the small intestine via the Slc12a8 transporter (identified in murine studies published in Nature Metabolism, 2019 [5]). Once inside cells, the NAMPT salvage pathway converts nicotinamide back to NMN, which is then adenylylated to form NAD+. This entire pathway operates independently of cytochrome P450 enzymes.

NR follows a parallel but distinct route. Nicotinamide riboside kinases (NRK1 and NRK2) phosphorylate NR directly to NMN, which is then converted to NAD+ [6]. A pharmacokinetic study published in Nature Communications (2016, N=12) showed dose-dependent increases in blood NAD+ following oral NR at 100, 300, and 1,000 mg, with no evidence of CYP-mediated interactions [6].

The CYP3A4 Concern Is Minimal Here

Because NMN and NR are endogenous-pathway supplements rather than CYP3A4 substrates, quercetin's enzyme inhibition does not meaningfully alter their metabolism. The interaction risk is pharmacokinetically negligible. This is a different situation from combining quercetin with, say, atorvastatin (a CYP3A4 substrate), where inhibition could raise statin plasma levels and increase myopathy risk.

Pharmacodynamic Considerations

Even when two compounds do not interact through liver enzymes, they can still produce additive or opposing effects at the tissue level. Quercetin and NMN/NR share several downstream targets worth examining.

Sirtuin Activation Overlap

NAD+ is the obligate co-substrate for sirtuins (SIRT1 through SIRT7), a family of deacetylases that regulate mitochondrial biogenesis, inflammation, and stress resistance. Quercetin has been shown to activate SIRT1 independently in cell culture, though at supraphysiologic concentrations [7]. Combining an NAD+ precursor with a mild sirtuin activator could produce additive benefits for mitochondrial function. No adverse pharmacodynamic interaction has been reported in this pathway.

AMPK and mTOR Signaling

Quercetin activates AMP-activated protein kinase (AMPK) and may inhibit mTOR signaling at high doses [8]. NMN, through its effects on NAD+ and SIRT1, also activates AMPK indirectly. Both compounds push cellular metabolism toward a catabolic, repair-oriented state. This convergence is generally considered favorable in the context of aging biology, but it does raise a theoretical flag for individuals who are underweight, malnourished, or recovering from surgery, where excessive catabolic signaling could impair tissue repair.

Anti-Inflammatory Effects

Quercetin is well-characterized as an NF-kB inhibitor and mast cell stabilizer, giving it both anti-inflammatory and antihistamine properties [9]. NAD+ repletion via NMN/NR also reduces inflammatory markers (IL-6, TNF-alpha) through sirtuin-mediated deacetylation of NF-kB subunits. In a 2021 randomized trial (N=48) published in the Journal of Clinical Endocrinology and Metabolism, NMN 250 mg/day reduced inflammatory markers in overweight postmenopausal women over 10 weeks [10]. The additive anti-inflammatory effect is unlikely to cause harm in otherwise healthy adults, but clinicians should be aware that patients on immunosuppressive therapy may experience exaggerated immune modulation.

Dose Timing and Practical Stacking Protocol

No clinical trial has established an optimal dosing schedule for the quercetin-NMN/NR combination. The following recommendations are extrapolated from the independent pharmacokinetic profiles of each supplement and general principles of supplement co-administration.

Suggested Timing

Take NMN or NR in the morning, ideally before 10 AM. NAD+ metabolism follows circadian patterns, with NAMPT expression peaking in the early part of the day. A 2020 study in Cell Reports showed that time-of-day administration affected the magnitude of NAD+ elevation in murine models [11]. Take quercetin with a fat-containing meal (the compound is lipophilic, and bioavailability increases 3- to 5-fold with dietary fat) [12]. Separate the two supplements by at least 1 hour, not because of a dangerous interaction, but to reduce the chance of GI discomfort from combining two compounds that can each independently cause mild nausea or stomach upset.

Dosing Ranges

For NMN: 250 to 500 mg per day is the most studied range. The Science trial used 600 and 900 mg/day [2], and higher doses appear safe but do not proportionally increase NAD+ levels.

For NR: 300 mg per day (as Niagen/TRU NIAGEN) is the most common commercial dose. The Airhart et al. (2017) safety trial used 1,000 mg twice daily without serious adverse events over 6 weeks [13].

For quercetin: 500 to 1,000 mg per day is the typical supplement dose. The Kirkland senolytic protocol used 1,250 mg combined with dasatinib, given intermittently (3 consecutive days per month) rather than daily [3].

Intermittent vs. Daily Quercetin

A growing body of opinion in longevity medicine favors intermittent quercetin dosing (e.g., 3 days on, 11 days off) rather than daily administration. The rationale is that senolytics need only periodic exposure to trigger apoptosis in senescent cells. Daily dosing is acceptable for quercetin's anti-inflammatory and antihistamine benefits, but the senolytic effect may not require it.

Monitoring Recommendations

Because neither NMN/NR nor quercetin requires a prescription in the United States, many users self-administer without baseline labs. A structured monitoring approach improves safety, especially for those combining multiple supplements.

Baseline Labs

Before starting either supplement, obtain a comprehensive metabolic panel (CMP), complete blood count (CBC), and liver function tests (AST, ALT, GGT). Quercetin, while generally well-tolerated, has rare case reports of hepatotoxicity at doses above 1,000 mg/day in susceptible individuals [14]. NMN and NR have not shown hepatotoxicity in clinical trials, but baseline values provide a reference point.

Follow-Up at 8 to 12 Weeks

Repeat liver function tests at 8 to 12 weeks. If AST or ALT rises above 2x the upper limit of normal, discontinue quercetin first (the more likely offender) and recheck in 4 weeks. Monitor for GI side effects throughout: nausea, bloating, and diarrhea are the most commonly reported complaints with both supplements.

Who Should Avoid This Combination

Pregnant or nursing individuals should not take either supplement due to insufficient safety data. Patients on fluoroquinolone antibiotics should avoid quercetin, which may chelate the drug and reduce absorption [15]. Individuals on warfarin should use quercetin cautiously, as it inhibits CYP2C9, the primary enzyme responsible for warfarin metabolism, and could increase bleeding risk [4].

What to Do If You Are Already Taking Both

If you have been combining quercetin and NMN/NR without issues, there is no clinical reason to stop. The absence of a meaningful pharmacokinetic interaction, combined with complementary pharmacodynamic profiles, makes this one of the lower-risk supplement pairings in the longevity category.

Steps to Optimize Your Current Protocol

First, confirm your doses fall within the studied ranges listed above. Second, if you have not checked liver enzymes since starting the combination, schedule a basic lab panel. Third, if you experience persistent GI symptoms (nausea lasting more than 2 weeks), try separating the doses by 2 hours and taking quercetin with a meal containing at least 10 to 15 grams of fat. Fourth, if you are taking quercetin daily for senolytic purposes, consider switching to an intermittent schedule (3 days per month) and reserving the daily dose only if you use quercetin for its antihistamine or anti-inflammatory effects.

Quercetin's Effect on Other NMN/NR Stack Companions

Many users who take NMN/NR and quercetin also stack resveratrol, fisetin, or TMG (trimethylglycine). Quercetin's CYP3A4 inhibition is more relevant for resveratrol, which undergoes significant hepatic metabolism via CYP1A2 and CYP3A4. A 2015 in vitro study showed that quercetin increased resveratrol's AUC (area under the curve) by approximately 30% in a simulated gut model [16]. This could theoretically amplify resveratrol's effects (both therapeutic and adverse). If you take all three, monitor for headaches and flushing, which are dose-dependent resveratrol side effects.

TMG is often co-administered with NMN to supply methyl groups consumed during NAD+ synthesis. Quercetin does not interfere with betaine-homocysteine methyltransferase, the enzyme responsible for TMG's methyl donation. No interaction is expected.

Fisetin is structurally similar to quercetin and shares its senolytic mechanism. Combining quercetin and fisetin at full doses is essentially doubling down on the same PI3K/AKT inhibition in senescent cells. Whether this produces additive benefit or simply additive GI side effects remains unstudied. Most longevity clinicians recommend choosing one or the other rather than stacking both flavonoid senolytics simultaneously.

The Bottom Line on Safety

The quercetin-NMN/NR combination carries low interaction risk. NMN and NR are metabolized through endogenous salvage pathways, not CYP450 enzymes. Quercetin's CYP3A4 inhibition, while clinically relevant for certain pharmaceuticals, does not meaningfully alter NAD+ precursor pharmacokinetics. The two supplements share complementary anti-aging mechanisms (senolytic clearance plus NAD+ repletion) with overlapping anti-inflammatory effects that are additive but not dangerous in healthy adults. Separate doses by 1 to 2 hours, take quercetin with dietary fat, check liver enzymes at baseline and 8 to 12 weeks, and avoid the combination if you are on warfarin, fluoroquinolones, or immunosuppressive therapy.